Ask AI
Back Back
EGFRm NSCLC Brain Metastases

CE / CME

Management of a Patient With EGFR-Mutated NSCLC and Brain Metastases

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: May 04, 2026

Expiration: November 03, 2026

Matthew Gubens
Matthew Gubens, MD, MS, FASCO
CME/CE Information

Activity

Progress
1 2
Course Completed

Case Conclusion
After local treatment of a symptomatic brain metastasis, the patient began Dato-DXd and achieved improvement in both systemic disease and brain lesions. Later, she developed grade 2 ILD/pneumonitis that improved with prompt corticosteroid treatment and drug interruption, but Dato-DXd was permanently discontinued in accordance with safety guidance. She and her care team now discuss next-line systemic options, weighing prior treatment exposures, remaining disease burden, and her goals of care.

Key Research and Case Summary
This case highlights several key principles in the management of EGFR-mutated NSCLC: new neurologic symptoms warrant prompt brain imaging; symptomatic or dominant brain metastases are best managed with local therapy such as stereotactic radiosurgery; Dato-DXd is an evidence-based option after progression on EGFR-directed therapy and platinum-based chemotherapy; and treatment-related toxicities, especially ILD/pneumonitis, require early recognition and decisive management.

Evaluation of New Neurologic Symptoms in EGFR-Mutated NSCLC
In this patient, the development of new neurologic symptoms after a period of systemic disease control raises immediate concern for CNS progression. Patients with EGFR-mutated NSCLC are at increased risk for brain metastases during the course of their disease, even when receiving CNS-penetrant EGFR TKIs such as osimertinib.

Guidelines recommend a low threshold for brain MRI in any patient with new neurologic symptoms, as early detection of CNS progression is critical to guide timely intervention and preserve neurologic function. Routine surveillance imaging alone may not be sufficient when new symptoms arise, and prompt diagnostic evaluation is essential to distinguish CNS progression from other potential causes.1,2

Management of Brain Metastases: Role of Local Therapy
In this patient, brain MRI confirmed a dominant, symptomatic brain metastasis with otherwise controlled systemic disease. This clinical scenario is commonly managed with local therapy, particularly when there is a limited number of lesions or a dominant symptomatic lesion.

Stereotactic radiosurgery is generally preferred over whole-brain radiation therapy in patients with limited brain metastases because it provides effective local control while minimizing neurocognitive toxicity. Whole-brain radiation therapy is typically reserved for patients with more diffuse CNS involvement or when stereotactic radiosurgery is not feasible.3 In patients with EGFR-mutated NSCLC, systemic therapy alone is often insufficient for symptomatic CNS lesions, and local treatment is prioritized to achieve rapid disease control.

Systemic Progression After EGFR TKI and Platinum Chemotherapy
After local CNS-directed therapy, this patient experienced systemic disease progression following prior osimertinib and platinum-based chemotherapy. In this setting, treatment options are limited, and prior exposures, disease burden, and available evidence should be considered when selecting subsequent therapy.

Historically, treatment options after EGFR TKI and platinum chemotherapy have included cytotoxic agents such as docetaxel, which have demonstrated modest efficacy, with response rates of approximately 10% to 15% and limited durability of response in previously treated NSCLC.4

Integration of TROP2 Antibody–Drug Conjugate Therapy: Dato-DXd
At this point in the patient’s disease course, Dato-DXd represents an evidence-based treatment option. Dato-DXd is a TROP2-directed antibody–drug conjugate with a topoisomerase I inhibitor payload. In the United States, it received FDA accelerated approval (June 23, 2025) for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.5

Efficacy for this indication was established in a pooled subgroup of 114 patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC who were enrolled across TROPION-Lung05 and TROPION-Lung01. In this analysis, the confirmed overall response rate was 45% (per blinded independent central review), with a median duration of response of 6.5 months.5 According to results from a pooled analysis of 117 patients published in 2025, the confirmed overall response rate was 43%, the median duration of response was 7.0 months, and the median progression-free survival was 5.8 months.6 These outcomes represent clinically meaningful activity in a setting where historical chemotherapy options have offered more limited and less durable benefit.

Emerging data also suggest intracranial activity with Dato-DXd in patients with NSCLC and baseline brain metastases. In a post hoc analysis of TROPION-Lung01, intracranial progression-free survival was numerically improved with Dato-DXd vs docetaxel in patients with brain metastases (median 5 vs 3 months with docetaxel). However, these findings should be interpreted with caution because the apparent CNS-specific benefit remains an exploratory post hoc finding and is not yet reflected in the current FDA label. Nevertheless, they reinforce why Dato-DXd is a strong option in a patient like this after local management of symptomatic CNS disease.7

Practical Toxicity Management With Dato-DXd
This patient later developed grade 2 ILD/pneumonitis after initially responding to Dato-DXd, illustrating the importance of proactive toxicity monitoring and management. Earlier in treatment, she also experienced grade 1 stomatitis, another common adverse event commonly seen with Dato-DXd that typically can be managed with supportive care while treatment continues.

ILD/pneumonitis is a serious and potentially life-threatening toxicity of Dato-DXd. In a pooled safety analysis of patients with NSCLC from TROPION-Lung01, TROPION-Lung05, and TROPION-PanTumor01, ILD/pneumonitis, including uncommon but clinically significant grade ≥3 events, occurred in 7% of patients overall, and the median time to onset was 1.4 months. Patients should be monitored for new or worsening cough, dyspnea, hypoxia, or radiographic infiltrates. Proactive patient education is a critical component of safe Dato-DXd administration. Patients should be counseled at treatment initiation to promptly report any new or worsening respiratory symptoms, including cough, shortness of breath, or chest discomfort, as early recognition is essential for timely intervention. If ILD/pneumonitis is suspected, Dato-DXd should be withheld, and corticosteroids should be considered at initial suspicion. For confirmed grade ≥2 ILD/pneumonitis, permanent discontinuation is recommended, even if symptoms resolve, and corticosteroids should be initiated promptly.5

In a different pooled safety analysis, stomatitis occurred in 63% of patients treated with Dato-DXd, with grade 3 events reported in 8% and 1 grade 4 reaction. The median time to first onset was 0.5 months. The prescribing information recommends prophylaxis, including steroid-containing mouthwash and oral ice during infusion, from treatment initiation, with escalation of supportive care if stomatitis develops. For grade 1 stomatitis, treatment may continue at the current dose with optimized supportive care.5

Do you plan to make any changes in your clinical practice based on what you learned in today’s program?